Profiling EGFR and Her2 in Breast Cancer using Multiplex Tissue Immunostaining

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$117,930.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA123994-01A2
Award Id:
85395
Agency Tracking Number:
CA123994
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
20/20 GENESYSTEMS, INC., 9700 GREAT SENECA HWY, ROCKVILLE, MD, 20850
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
136134686
Principal Investigator:
WILLIAM JAMES
(301) 435-7882
BJAMES@2020GENE.COM
Business Contact:
JONATHAN COHEN
() -
gtroy@202gene.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies, including Herceptin(r) and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary layered peptide array (LPA) technology. Transfer of antibody probes from a single tissue section to numerous bioaffinity me mbranes permits multiple target antigens (up to 50 if needed) to be assessed in a quantitative manner while preserving the local spatial orientation of the targets relative to the tissue section. The immediate goals are to develop a panel of 7 assays (comp rising antigen-coated membranes and relevant antibodies), and to demonstrate their use for profiling AKT signaling in cultured breast cancer cells and archival tissues. During Phase II, we will demonstrate its tissue applications with animal models, and wi th human breast tissue sections from clinical trials in breast cancer patients treated with growth factor and Akt inhibitors. The product would have utility in both a research and clinical laboratory setting. Importantly, the system is open-ended to the ad dition of new prognostic markers and drug targets into the assay panel. There are several anticipated advantages of the layered membrane platform over current histopathology tools such as immunohistochemistry (IHC). These include conservation of tissue (su ch as for core needle biopsies) and the ability to simultaneously profile multiple signaling proteins in both normal and phosphorylated form. Our options for breast cancer diagnosis and treatment will increasingly take advantage of information obtained fro m tumor profiling assays, which will indicate customized therapies for each form of the disease. The novel diagnostic techniques to be researched will allow for microscopic profiling of tiny amounts of tissue for numerous cancer-causing molecules. There wi ll be applications in pre-clinical studies and drug trials, which will aim to invent novel treatment strategies using combinations of drugs that block 'growth factor' molecules.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government